The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 09, 2023
Filed:
Mar. 10, 2017
Applicant:
Scholar Rock, Inc., Cambridge, MA (US);
Inventors:
Thomas Schurpf, Cambridge, MA (US);
Gregory J. Carven, Maynard, MA (US);
Abhishek Datta, Boston, MA (US);
Kimberly Long, Boston, MA (US);
Assignee:
Scholar Rock, Inc., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/22 (2006.01); A61P 21/00 (2006.01); A61P 13/12 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/22 (2013.01); A61K 39/39558 (2013.01); A61P 13/12 (2018.01); A61P 21/00 (2018.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/32 (2013.01); C07K 2317/33 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract
Disclosed herein are immunoglobulins, such as antibodies, and antigen binding portions thereof, that specifically bind complexes of GARP-TGFβ1, LTBP1-TGFβ1, LTBP3-TGFβ1, and/or LRRC33-TGFβ1. The application also provides methods of use of these immunoglobulins for, for example, inhibiting TGFβ1 activity, and treating subjects suffering from TGFβ1-related disorders, such as cancer and fibrosis.